Get started
Author

Justyna E. Kanska

Cyclin E as a potential therapeutic target in high grade serous ovarian cancer
2016 · J. Kanska, M. Zakhour, et al. · Gynecologic Oncology · 95
Induced stem cell neoplasia in a cnidarian by ectopic expression of a POU domain transcription factor
2011 · R. Cathriona Millane, Justyna Kanska, et al. · Development · 83
Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT
2017 · Justyna Kanska, Paul-Joseph P. Aspuria, et al. · Oncotarget · 46
PDF
Novel roles for Nanos in neural cell fate determination revealed by studies in a cnidarian
2013 · Justyna Kanska, Uri Frank · Journal of Cell Science · 41
Functional studies on the role of Notch signaling in Hydractinia development
2017 · James M. Gahan, Christine E. Schnitzler, et al. · Developmental Biology · 31
PDF
CAR-T manufactured from frozen PBMC yield efficient function with prolonged in vitro production
2022 · Julieta Abraham-Miranda, Meghan Menges, et al. · Frontiers in Immunology · 16
PDF
New roles for Nanos in neural cell fate determination revealed by studies in a cnidarian
2013 · Justyna Kanska, Uri Frank · Development · 13
ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
2022 · Matthew S. Davids, Saad S. Kenderian, et al. · Blood · 12
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3
2025 · Tom van Meerten, Marie José Kersten, et al. · Blood · 10
ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia
2025 · Matthew S. Davids, Saad S. Kenderian, et al. · Blood · 10
Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.
2022 · Paolo Strati, Lori Ann Leslie, et al. · Journal of Clinical Oncology · 10
Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma
2026 · Eli P. Darnell, Kathleen M. E. Gallagher, et al. · Blood Advances · 6
A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363
2025 · Saurabh Dahiya, Matthew Ulrickson, et al. · Blood · 6
PDF
Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
2024 · Tom van Meerten, M.J. Kersten, et al. · Blood · 6
PDF
A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).
2025 · Saurabh Dahiya, Matthew Ulrickson, et al. · Journal of Clinical Oncology · 4
Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial
2026 · Paolo Strati, Lori Leslie, et al. · Nature Cancer · 1
PDF
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9-mediated truncating mutations in BRCA1 and BRCA2 genes lead to increased baseline genetic instability and diminished growth in fallopian tube epithelial cell line
2019 · Z.P. Schwartz, J. Kanska, et al. · Gynecologic Oncology · 1
A Phase 1 Study of KITE-753 or KITE-363 in Patients with Relapsed/Refractory B-cell Lymphoma: Initial Safety and Preliminary Efficacy of KITE-753 and Updated Results of KITE-363
2026 · Saurabh Dahiya, Matthew L. Ulrickson, et al. · Transplantation and Cellular Therapy
103 | a Phase 1 Study of Kite‐363 Anti‐cd19/cd20 Chimeric Antigen Receptor (car) T‐cell Therapy in Patients With Relapsed/refractory (r/r) B‐cell Lymphoma
2025 · S. Dahiya, M. L. Ulrickson, et al. · Hematological Oncology
PDF
193 CAR-T manufactured from frozen PBMC yield efficient function with delayed in vitro expansion
2022 · Julieta Abraham-Miranda, Meghan Menges, et al. · Regular and Young Investigator Award Abstracts
PDF
P1197: Axicabtagene Ciloleucel (axi-cel) in Combination With Rituximab for the Treatment of Relapsed/refractory (r/r) Large B-cell Lymphoma (lbcl): Outcomes of the Phase 2 Zuma-14 Study
2022 · P. Strati, L. Leslie, et al. · HemaSphere
Deciphering functional mechanisms underlying the 6q23.1 breast cancer risk locus
2021 · Saeideh Torabi Dalivandan, Stephanie Chen, et al. · Molecular Genetics and Metabolism
Transcriptome and interactome analyses identify the TP53 interacting gene RCCD1 as a candidate susceptibility gene at the 15p26.1 breast and ovarian cancer risk locus
2020 · Jasmine Plummer, Felipe Segato Dezem, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Abstract 1734: Crispr/Cas9 screening of Brca1 and Brca2 susceptibility genes in breast and ovarian cancer precursor cells can identify phenotypically different mutants with variable penetrance
2019 · Justyna Kanska, Kruttika Dabke, et al. · Molecular and Cellular Biology / Genetics
Abstract 1734: Crispr/Cas9 screening of Brca1 and Brca2 susceptibility genes in breast and ovarian cancer precursor cells can identify phenotypically different mutants with variable penetrance
2019 · Justyna Kanska, Kruttika Dabke, et al. · Cancer Research
Works count: 33
Citation count: 391
H-index: 10
I10-index: 11
Year
Topic
Type